Study patient demographic and clinical characteristics
| . | Overall alloHSCT patients, n (%) . | Propensity-matched analysis . | |
|---|---|---|---|
| alloHSCT-NIPC patients, n (%) . | alloHSCT non-NIPC patients, n (%) . | ||
| Total patients | 2167 | 155 | 155 |
| Female, n (%) | 1004 (46) | 61 (39) | 58 (37) |
| Age (years), mean ± SD | 42.9 ± 17.3 | 51.1 ± 12.9 | 50.2 ± 14.1 |
| Age groups, n (%) | |||
| <18 y | 259 (12) | *** | *** |
| 18-40 y | 536 (25) | 21 (14) | 20 (13) |
| 41-64 y | 1367 (63) | 129 (83) | 127 (82) |
| Geographic region, n (%) | |||
| Midwest | 734 (34) | 61 (39) | 61 (39) |
| Northeast | 478 (22) | 34 (20) | 28 (18) |
| South | 768 (36) | 52 (34) | 54 (35) |
| West | 167 (8) | 11 (7) | 12 (8) |
| Health plan type, n (%) | |||
| Preferred provider organization | 1781 (82) | 128 (83) | 133 (86) |
| Point of service | 74 (3) | *** | *** |
| Health maintenance organization | 233 (11) | 14 (9) | 12 (8) |
| Other | 61 (3) | *** | *** |
| Year of transplant, n (%) | |||
| 2007 | 107 (5) | *** | *** |
| 2008-2009 | 381 (18) | 37 (24) | 29 (19) |
| 2010-2011 | 417 (19) | 37 (24) | 17 (11) |
| 2012-2013 | 468 (22) | 30 (19) | 38 (25) |
| 2014-2015 | 452 (21) | 29 (19) | 33 (21) |
| 2016-Q32017 | 337 (16) | 16 (10) | 30 (19) |
| Clinical characteristics, n (%) | |||
| Myocardial infarction | 71 (3) | *** | *** |
| Congestive heart failure | 234 (11) | 24 (15) | 15 (10) |
| Peripheral vascular disease | 123 (6) | 13 (8) | 12 (8) |
| Cerebrovascular disease | 110 (5) | *** | 11 (7) |
| Dementia | *** | 0 (0) | *** |
| Asthma | 419 (19) | 41 (26) | 29 (19) |
| Rheumatic disease | 54 (2) | *** | *** |
| Peptic ulcer disease | 23 (1) | *** | 0 (0) |
| Liver disease | 415 (19) | 40 (26) | 33 (21) |
| Diabetes | 310 (14) | 30 (19) | 22 (14) |
| Hemiplegia or paraplegia | 22 (1) | *** | *** |
| Renal disease | 124 (6) | 14 (9) | *** |
| Cancer | 1678 (78) | 146 (94) | 136 (88) |
| HIV/AIDS | *** | 0 (0) | 0 (0) |
| Charlson comorbidity index score, mean ± SD | 3.0 ± 2.3 | 3.5 ± 2.1 | 3.3 ± 2.2 |
| Time period patients observable | |||
| 12+ months | 2162 (100) | 155 (100) | 155 (100) |
| 24+ months | 1305 (60) | 73 (47) | 74 (48) |
| 36+ months | 825 (38) | 47 (30) | 47 (30) |
| 48+ months | 564 (26) | 33 (21) | 31 (20) |
| 60+ months | 366 (17) | 21 (14) | 18 (12) |
| Year of NIPC diagnosis | |||
| Year 1 after transplantation | 135 (53) | 79 (51) | — |
| Year 2 after transplantation | 79 (31) | 50 (32) | — |
| Year 3 after transplantation | 24 (10) | 15 (10) | — |
| Year 4 or 5 after transplantation | 16 (6) | 11 (7) | — |
| . | Overall alloHSCT patients, n (%) . | Propensity-matched analysis . | |
|---|---|---|---|
| alloHSCT-NIPC patients, n (%) . | alloHSCT non-NIPC patients, n (%) . | ||
| Total patients | 2167 | 155 | 155 |
| Female, n (%) | 1004 (46) | 61 (39) | 58 (37) |
| Age (years), mean ± SD | 42.9 ± 17.3 | 51.1 ± 12.9 | 50.2 ± 14.1 |
| Age groups, n (%) | |||
| <18 y | 259 (12) | *** | *** |
| 18-40 y | 536 (25) | 21 (14) | 20 (13) |
| 41-64 y | 1367 (63) | 129 (83) | 127 (82) |
| Geographic region, n (%) | |||
| Midwest | 734 (34) | 61 (39) | 61 (39) |
| Northeast | 478 (22) | 34 (20) | 28 (18) |
| South | 768 (36) | 52 (34) | 54 (35) |
| West | 167 (8) | 11 (7) | 12 (8) |
| Health plan type, n (%) | |||
| Preferred provider organization | 1781 (82) | 128 (83) | 133 (86) |
| Point of service | 74 (3) | *** | *** |
| Health maintenance organization | 233 (11) | 14 (9) | 12 (8) |
| Other | 61 (3) | *** | *** |
| Year of transplant, n (%) | |||
| 2007 | 107 (5) | *** | *** |
| 2008-2009 | 381 (18) | 37 (24) | 29 (19) |
| 2010-2011 | 417 (19) | 37 (24) | 17 (11) |
| 2012-2013 | 468 (22) | 30 (19) | 38 (25) |
| 2014-2015 | 452 (21) | 29 (19) | 33 (21) |
| 2016-Q32017 | 337 (16) | 16 (10) | 30 (19) |
| Clinical characteristics, n (%) | |||
| Myocardial infarction | 71 (3) | *** | *** |
| Congestive heart failure | 234 (11) | 24 (15) | 15 (10) |
| Peripheral vascular disease | 123 (6) | 13 (8) | 12 (8) |
| Cerebrovascular disease | 110 (5) | *** | 11 (7) |
| Dementia | *** | 0 (0) | *** |
| Asthma | 419 (19) | 41 (26) | 29 (19) |
| Rheumatic disease | 54 (2) | *** | *** |
| Peptic ulcer disease | 23 (1) | *** | 0 (0) |
| Liver disease | 415 (19) | 40 (26) | 33 (21) |
| Diabetes | 310 (14) | 30 (19) | 22 (14) |
| Hemiplegia or paraplegia | 22 (1) | *** | *** |
| Renal disease | 124 (6) | 14 (9) | *** |
| Cancer | 1678 (78) | 146 (94) | 136 (88) |
| HIV/AIDS | *** | 0 (0) | 0 (0) |
| Charlson comorbidity index score, mean ± SD | 3.0 ± 2.3 | 3.5 ± 2.1 | 3.3 ± 2.2 |
| Time period patients observable | |||
| 12+ months | 2162 (100) | 155 (100) | 155 (100) |
| 24+ months | 1305 (60) | 73 (47) | 74 (48) |
| 36+ months | 825 (38) | 47 (30) | 47 (30) |
| 48+ months | 564 (26) | 33 (21) | 31 (20) |
| 60+ months | 366 (17) | 21 (14) | 18 (12) |
| Year of NIPC diagnosis | |||
| Year 1 after transplantation | 135 (53) | 79 (51) | — |
| Year 2 after transplantation | 79 (31) | 50 (32) | — |
| Year 3 after transplantation | 24 (10) | 15 (10) | — |
| Year 4 or 5 after transplantation | 16 (6) | 11 (7) | — |
This table describes the demographics and comorbidities for the overall alloHSCT cohort, as well as the propensity-matched NIPC and non-NIPC alloHSCT patients.
Among all alloHSCT patients, 254 developed NIPC, but only 155 were propensity-matched. These totals were used to calculate percentages in the year of index NIPC diagnosis. ***, patient count was <11.